Silverback Therapeutics, Inc. SBTX
Institutional shares held
83.8 Million
1.21M
calls
687K
puts
Total value of holdings
$0
$0
calls
$0
puts
Market Cap
N/A
Institutional ownership
236.14%
# of Institutions
209
We take great care to ensure that the data presented and summarized in this overview for Silverback Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SBTX
View all-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY7.5MShares$00.0% of portfolio
-
Rubric Capital Management LP New York, NY4.5MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$00.0% of portfolio
-
Abrdn PLC3.1MShares$00.0% of portfolio
-
State Street Corp Boston, MA2.9MShares$00.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.64MShares$00.0% of portfolio
Latest Institutional Activity in SBTX
Top Purchases
Top Sells
About SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Transactions at SBTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 13
2025
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
21,828
-66.92%
|
$174,624
$8.71 P/Share
|
|
Nov 13
2025
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,828
+40.09%
|
$0
$0.64 P/Share
|
|
Nov 12
2025
|
Pratik Shah |
SELL
Bona fide gift
|
Indirect |
350,000
-3.68%
|
-
|
|
Nov 12
2025
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
166,380
-59.02%
|
$1,331,040
$8.89 P/Share
|
|
Nov 12
2025
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+15.28%
|
$0
$0.84 P/Share
|
|
Aug 21
2025
|
Kathleen D. Scott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-55.45%
|
$187,500
$15.0 P/Share
|
|
Aug 21
2025
|
Kathleen D. Scott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+35.67%
|
$12,500
$1.5 P/Share
|
|
Aug 21
2025
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
50,000
-4.01%
|
$700,000
$14.49 P/Share
|
|
Aug 20
2025
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
37,656
-2.93%
|
$527,184
$14.09 P/Share
|
|
Aug 19
2025
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
12,344
-0.95%
|
$172,816
$14.03 P/Share
|
|
Jul 01
2025
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-59.25%
|
$240,000
$16.99 P/Share
|
|
Jul 01
2025
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+37.21%
|
$15,000
$1.5 P/Share
|
|
Jun 27
2025
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
740,149
-7.04%
|
$13,322,682
$18.46 P/Share
|
|
Jun 18
2025
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-66.09%
|
$240,000
$16.0 P/Share
|
|
Jun 18
2025
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+39.79%
|
$15,000
$1.5 P/Share
|
|
May 20
2025
|
Kathleen D. Scott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-87.07%
|
$700,000
$14.1 P/Share
|
|
May 20
2025
|
Kathleen D. Scott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+46.54%
|
$50,000
$1.5 P/Share
|
|
May 20
2025
|
Brent L Saunders |
SELL
Open market or private sale
|
Direct |
120,000
-100.0%
|
$1,680,000
$14.25 P/Share
|
|
May 20
2025
|
Brent L Saunders |
BUY
Exercise of conversion of derivative security
|
Direct |
120,000
+50.0%
|
$120,000
$1.01 P/Share
|
|
May 20
2025
|
Alexander A Fitzpatrick Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
102,969
-53.47%
|
$1,441,566
$14.1 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.33M
Shares
From
9
Insiders
| Exercise of conversion of derivative security | 1.33M shares |
|---|
Sell / Disposition
2.98M
Shares
From
11
Insiders
| Open market or private sale | 2.63M shares |
|---|---|
| Bona fide gift | 350K shares |